Home  »  Finance   »  What’s Up With Lexicon Pharmaceuticals Inc (...

What’s Up With Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)?

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) price closed higher on Monday, February 12, jumping 22.18% above its previous close.

A look at the daily price movement shows that the last close reads $2.39. The company’s 5Y monthly beta was ticking 1.23. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.79 and 52-week low of $0.92. The stock added 107.09% on its value in the past month.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Lexicon Pharmaceuticals Inc, which has a market valuation of $715.20 million, is expected to release its quarterly earnings report Feb 29, 2024 – Mar 04, 2024.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give LXRX a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy.

The overview shows that LXRX’s price is at present 63.45% off the SMA20 and 92.96% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 82.31, with weekly volatility standing at 11.75%. The indicator jumps to 10.04% when calculated based on the past 30 days. Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s beta value is holding at 1.26, while the average true range (ATR) indicator is currently reading 0.19.

Turning out attention to how the Lexicon Pharmaceuticals Inc stock has performed in comparison to its peers in the industry, here’s what we find: LXRX’s stock is 22.18% on the day and 26.41% in the past 12 months, while Thermo Fisher Scientific Inc. (TMO) traded -0.71%% in the last session and was positioned -4.89% down on its price 12 months ago. Turning out attention to how the Lexicon Pharmaceuticals Inc stock has performed in comparison to its peers in the industry, here’s what we find: LXRX’s stock is 22.18% on the day and 26.41% in the past 12 months, while Thermo Fisher Scientific Inc. (TMO) traded -0.71%% in the last session and was positioned -4.89% down on its price 12 months ago. Another comparison is with Ligand Pharmaceuticals Inc. (LGND) whose stock price was down -0.32%% in the last trading session, and has flourished 6.10% over the past year. Also, Regeneron Pharmaceuticals Inc. (REGN) showed down trend of -0.67%% while its price kept floating at 23.97% over the past year.

An analysis of the Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) stock in terms of its daily trading volume indicates that the 3-month average is 3.11. However, this figure increases on the past 10-day timeline to an average of 4.48 million.

Current records show that the company has 244.93M in outstanding shares. The insiders’ percentage holdings are 2.51% of outstanding shares while the percentage share held by institutions stands at 76.05%. The stats also highlight that short interest as of Jan 31, 2024, stood at 23.03 million shares, which puts the short ratio at the time at 6.35. From this we can glean that short interest is 9.44% of company’s current outstanding shares. Notably, we see that shares short in January fall slightly given the previous month’s figure stood at 23.22 million. But the 90.85% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.